Allurion Q4 2024 Earnings Report
Key Takeaways
The company reported Q4 2024 revenue of $5.6 million, down from $8.2 million in the prior year. Gross margin declined to 45% due to lower production volumes and inventory adjustments. Operating expenses were reduced significantly, contributing to a lower net loss compared to previous quarters.
Q4 2024 revenue was $5.6 million, down from $8.2 million in Q4 2023.
Gross profit margin decreased to 45%, impacted by lower volumes and inventory adjustments.
Operating expenses decreased by 39% year-over-year, reflecting restructuring efforts.
Net loss for Q4 2024 totaled $20.6 million compared to $19.2 million in Q4 2023.
Allurion
Allurion
Allurion Revenue by Segment
Forward Guidance
Allurion expects $30 million in revenue for 2025 with further reductions in operating expenses and continued commercial expansion, particularly after resuming sales in France.
Positive Outlook
- Resumption of sales in France as of February 2025.
- Launch of next-generation Allurion Balloon with improved features.
- Positive topline results from the AUDACITY FDA clinical trial.
- Expected gross margin improvement as inventory normalizes.
- Recent financings provide runway through expected FDA approval.
Challenges Ahead
- Revenue decline driven by temporary suspension in France.
- Lower production volumes impacting cost absorption.
- Significant restructuring charges incurred in Q4 2024.
- Continued macroeconomic headwinds affecting re-orders.
- High net loss and operational expenses still present challenges.